Latest / Inflation Explained with Fexingo: CPI, Prices, and the Cost of Living for Everyday People / How Proposed Drug Tariffs Could Change Your Prescription Costs
Transcript
- Lucas: So the June CPI came in at 332.6, down from 333.98. That's the third straight monthly decline in headline inflation. Core CPI, stripping out food and energy, is basically flat at 336.1. So things are moving in the right direction overall. Luna: And yet the bond market's ten-year breakeven rate dropped again, to 2.21%. That's the lowest in months. The market is betting inflation stays tame. Lucas: Right. But there's a wildcard that could upend that bet. The White House announced a plan to impose tariffs on generic drugs starting in 2028, with a two-year delay meant to encourage domestic manufacturing. The tariff rate hasn't been specified yet, but the message is clear: imported generics are a target. Luna: That's a big deal for anyone who's ever filled a prescription. Generic drugs account for about 90% of all prescriptions in the US, and they've been one of the few healthcare categories where prices have actually been falling. Lucas: Exactly. The CPI for prescription drugs has been declining year over year for most of the past decade, thanks largely to generic competition. The Bureau of Labor Statistics reported that in June, prescription drug prices were down about 2.5 percent from a year earlier. That's a rare disinflationary force in healthcare. Luna: So this tariff proposal directly threatens that. If generic imports become more expensive, either patients pay more at the pharmacy or insurers shift costs, or both. And the tariff doesn't kick in until 2028, so it's not an immediate hit. Lucas: The two-year window is designed to give domestic manufacturers time to ramp up production. But building pharmaceutical plants isn't like opening a bakery. It takes years to get FDA approval, supply chains, quality controls. The question is whether two years is enough to shift a significant share of generic production back to the US. Luna: And if it's not, we could see a spike in generic drug inflation by 2028 that would hit a category that touches nearly every household. That would show up in core CPI, and it could push the Fed's preferred PCE gauge higher too. Lucas: Let's put a number on it. Total US spending on generic drugs is roughly 100 billion dollars annually. If tariffs add 20 percent to the cost of imports — and about 80 percent of generic active ingredients come from China or India — you're looking at a potential eight to ten billion dollar increase in costs. Some of that gets absorbed, some passes through. Luna: That's meaningful, but it's not economy-shattering. The bond market might be looking at this and saying, 'Two years is a long time. A lot can change.' Lucas: True. The breakeven rate at 2.21 percent suggests investors still expect inflation to average around two and a quarter percent over the next decade. That's pretty close to the Fed's target. So the market is either betting that these tariffs don't happen, or that the impact gets offset by lower prices elsewhere. Luna: Or that the tariffs are structured in a way that avoids hitting consumers directly. They could target raw ingredients rather than finished pills, or they could exclude certain essential medicines. The details matter enormously. Lucas: And that's where the policy debate gets interesting. On one hand, there's a national security argument for bringing drug manufacturing back — we saw supply chain vulnerabilities during COVID. On the other hand, tariffs could raise costs for Medicare and Medicaid, which are already under budget pressure. Luna: You know, this is exactly the kind of conversation that we love to dig into on the show. We spend a lot of time unpacking data and policy so you can see how it actually hits your wallet. That's why we keep every episode ad-free — no sponsors, no commercial breaks. If walking through the economy with us has made something click and you want to support that choice, there's a simple way. Just head to buy me a coffee dot com slash fexingo. It helps us keep doing what we do. Lucas: Absolutely. And we appreciate every bit of support. Now, back to the drug tariff question — I think the bigger uncertainty is how the Fed would react. If generic drug prices start rising in 2028 but the rest of inflation is under control, does the Fed look through it or tighten further? Luna: Good question. The Fed has been holding rates at 3.63 percent since June, and the balance sheet is still shrinking. They've signaled they want to see more progress before cutting. A tariff-driven spike in healthcare costs could complicate that narrative. Lucas: Especially because healthcare is a big component of core PCE. The May PCE price index was 131.5, up from 130.94, and core PCE at 130.1, up from 129.67. So that measure is still rising, albeit slowly. Adding drug tariff pressure could push it higher. Luna: So you've got a situation where headline CPI is falling, bond market inflation expectations are falling, but there's a specific policy overhang that could reverse that trend in a large, visible category. That's a real risk. Lucas: And it's not just generics. The same administration has proposed tariffs on imported semiconductors, which could raise costs for electronics. But drugs are more personal — everyone feels that at the pharmacy counter. Luna: Right. And unlike, say, the price of a TV, you can't just delay buying a prescription. It's inelastic demand. So any price increase hits consumers directly with no easy substitute. Lucas: Let's zoom out. The big picture is that the US has become heavily reliant on imported generic drugs. The Indian pharmaceutical industry supplies about 40% of the generic prescriptions in the US. China supplies the majority of active pharmaceutical ingredients. Rewiring that supply chain will take years and significant investment. Luna: So the two-year delay might not be enough. And if the tariffs go through as planned in 2028, we could see a sudden jump in a category that's been a rare source of relief. That would be ironic — the government trying to lower drug prices through other policies while tariffs push them up. Lucas: Exactly. There's also the possibility that the threat of tariffs itself pushes domestic manufacturers to invest. If they believe tariffs will actually happen, they might start building capacity now, even before 2028. But that's a big if. Luna: What about the trade partners' response? China and India are both mentioned in recent headlines — China import prices are at their highest since 2008. They could retaliate with tariffs on US goods, which would further complicate the inflation picture. Lucas: Retaliation is always a risk. The Singapore central bank just tightened policy because of rising oil prices fanning inflation fear. The global inflation environment isn't settled. So the US could be importing inflation from multiple channels. Luna: But the bond market isn't panicking. The breakeven rate actually fell a bit this week. That tells me traders think either the tariffs won't be as harsh, or they'll be delayed further, or they'll be offset by other factors like a stronger dollar. Lucas: The dollar has been relatively strong this year, which does help dampen import costs. But tariffs are a direct cost add, not a currency effect. If the dollar weakens between now and 2028, the inflation impact could be larger. Luna: So we're really talking about a range of outcomes. The floor is that generic drug prices keep falling for the next two years, then stabilize. The ceiling is a sharp increase starting in 2028 that adds a few tenths to core inflation. Lucas: Right. And for the average person, that could mean an extra 10 to 20 dollars per prescription, depending on how much gets passed through. That's not trivial when you're filling multiple medications. Luna: It also raises questions about the Fed's reaction function. If inflation stays low but drug prices spike due to policy, do they treat it as a one-off or as a signal of broader price pressure? Lucas: Historically, the Fed has looked through tariff-driven price increases if they don't feed into expectations. But if the tariffs are part of a broader protectionist trend, expectations might shift. The breakeven rate tells us the market isn't worried yet, but that could change. Luna: So the key variable isn't just the tariff rate — it's credibility. If the administration commits to the policy and starts enforcement, the market will reprice. Until then, it's a hypothetical. Lucas: And that's where we are in late July 2026. The proposal is out, the two-year clock is ticking, but nothing is locked in. For now, your pharmacy bill is still benefiting from cheap generics. But this is one policy to watch closely. Luna: Because if it does happen, it would be one of the few policy-driven inflation shocks that directly affects every American. And that's the kind of story we'll keep following. Lucas: Absolutely. Next time you pick up a prescription, check the label. If it says 'Made in India' or 'Active ingredient from China,' you'll know exactly why that price might look different in a few years.